According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 4.04%, which means ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

The “ Acute Myocardial Infarction Market Report ” by DelveInsight offers a robust analysis of market size, treatment ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Domestic ...

So on that alone, maybe yes. But what might this new US move mean for the industry overall, and for AstraZeneca shares specifically? Analyst Stefan Schneider at Bank Vontobel said it “has the ...

AstraZeneca aims to widen the pool of bladder ... AZ added, but a descriptive analysis “demonstrated no detriment" for the Imfinzi arm. Still, an improvement in disease-free survival is ...

As health systems across the Middle East and Africa confront the dual pressures of rising non-communicable diseases (NCDs) and persistent access gaps, AstraZeneca is placing health equity at the ...

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...